News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Legora Acquires Cadastral to Enter Commercial Real Estate
Legora bought Cadastral, an AI platform automating commercial real estate workflows used by JLL and AvalonBay. The move anchors Legora's US expansion, targeting 300+ North American staff by end-2026.
Microsoft builds its own frontier AI to cut OpenAI dependence
Microsoft unveiled MAI-Thinking-1, claiming parity with Claude Opus 4.6, plus updated speech, text and code models. The move signals a shift toward owning its AI stack.
Litera embeds CRM into Microsoft 365 for law firms dodging data entry
Litera's Foundation 365 now integrates client relationship data directly into Outlook, Teams and Copilot. The platform serves 99% of Am Law 100 firms and 2.3M daily users.
Your QC Lab Needs a Control Strategy, Not Just More Samples
Pharmaceutical labs often chase measurement certainty by increasing sample size. Contract Pharma explains why a lifecycle-based control strategy focused on bias and variability matters more.
40% of pharma firms say cost-cutting is breaking quality, FDA responds with AI audits
Cytiva's 2025 survey of 1,250 biopharma executives reveals quality decline across outsourced manufacturing. Risk-based systems—not compliance theater—offer a way out.
85% of bladder cancer patients avoided surgery with durvalumab boost
Phase 2 trial shows adding immunotherapy durvalumab to chemoradiation kept muscle-invasive bladder cancer at bay for 85% of patients at one year — without removing the bladder.
Eli Lilly's in vivo CAR-T shows safer profile than AstraZeneca rival in early myeloma trial
Kelonia's KLN-1010 delivered responses in all 18 patients with manageable toxicity, but durability data remains sparse and prior BCMA therapy exposure is unclear.
Eli Lilly's RET drug cuts recurrence risk 83% in early lung cancer
Retevmo reduced event-free survival risk by 83% in a 151-patient adjuvant NSCLC trial. The win opens a rare but underexplored patient population — if genetic testing keeps pace.
Roche's breast cancer drug wins FDA priority review by late 2026
Giredestrant cut recurrence risk by 30% in Phase III trials. The oral therapy targets early-stage ER-positive breast cancer where cure odds are highest—FDA decision expected by November 2026.
AbbVie wins EC approval for Aquipta migraine acute treatment
European Commission approves Aquipta (atogepant) for acute migraine in adults. AbbVie now offers both acute and preventive migraine treatments in the EU.
Contraline raises $92.5M to test first male contraceptive pill in 2027
Google Ventures-backed Contraline is funding Phase III trials of NES/T Gel, a daily topical male contraceptive. If successful, it could be the first hormonal birth control approved for men.
$3.6B in biotech funding fuels AI drug design and clinical trials
Isomorphic Labs, Apogee Therapeutics, and Avalo raised $3.6 billion combined in May 2026. Here's where the money went and what it means for drug pipelines.